Edition:
India

Neurocrine Biosciences Inc (NBIX.OQ)

NBIX.OQ on NASDAQ Stock Exchange Global Select Market

70.59USD
11 Dec 2017
Change (% chg)

$-3.16 (-4.28%)
Prev Close
$73.75
Open
$74.06
Day's High
$74.06
Day's Low
$70.51
Volume
370,363
Avg. Vol
347,654
52-wk High
$75.87
52-wk Low
$37.37

Latest Key Developments (Source: Significant Developments)

Neurocrine Biosciences appoints Matt Abernethy as CFO
Tuesday, 21 Nov 2017 

Nov 20 (Reuters) - Neurocrine Biosciences Inc ::Neurocrine Biosciences appoints Matt Abernethy as chief financial officer.Neurocrine Biosciences Inc - announced that Matt Abernethy is joining executive management team as chief financial officer​.  Full Article

Neurocrine Biosciences reports Q3 loss per share $0.13
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Neurocrine Biosciences Inc :Neurocrine Biosciences reports third quarter 2017 results.Q3 loss per share $0.13.Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S.Says net product sales of $45.8 million for three months ended September 30, 2017​.  Full Article

Abbvie receives U.S. FDA priority review for investigational Oral Treatment Elagolix
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Abbvie Inc :Abbvie receives U.S. FDA priority review for Investigational Oral Treatment Elagolix for the management of Endometriosis with associated pain.Abbvie inc - ‍expects PDUFA date for FDA to complete its review will be in Q2 2018​.  Full Article

Neurocrine initiates Phase IIb clinical study of Ingrezza
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - Neurocrine Biosciences Inc :Neurocrine initiates phase IIb clinical study of once-daily Ingrezza in children and adolescents with Tourette syndrome.Neurocrine Biosciences Inc - ‍top-line data from study is expected in late 2018​.  Full Article

Neurocrine granted FDA orphan drug designation for Valbenazine
Tuesday, 24 Oct 2017 

Oct 23 (Reuters) - Neurocrine Biosciences Inc :Neurocrine granted FDA orphan drug designation for valbenazine for the treatment of pediatric patients with Tourette syndrome.  Full Article

Neurocrine Biosciences says David-Alexander Gros resigns as COO and interim CFO of co
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Neurocrine Biosciences Inc :Neurocrine Biosciences Inc - ‍on Oct. 18, David-Alexander C. Gros resigned as president, COO and interim CFO of co, effective as of Oct. 19 - SEC filing.Neurocrine Biosciences Inc - ‍in connection with resignation of Gros, effective Oct. 19, Kevin C. Gorman​ was appointed as company's interim CFO.  Full Article

Neurocrine Bio's Ingrezza fails study in pedriatric Tourette's patients
Wednesday, 24 May 2017 

May 23 (Reuters) - Neurocrine Biosciences Inc :Neurocrine announces phase ii results of vmat2 inhibitor ingrezza® for treatment of tourette syndrome.Neurocrine biosciences inc- study did not meet its primary endpoint.Neurocrine biosciences inc- there were a total of four discontinuations due to adverse events, two in each of placebo and ingrezza arms in study.Neurocrine biosciences inc- company is also conducting an open-label, fixed-dose study of ingrezza in up to 180 subjects with tourette syndrome.  Full Article

Neurocrine and Bial reports exclusive North American licensing agreement for opicapone
Friday, 10 Feb 2017 

Neurocrine Biosciences Inc : Neurocrine and Bial announce exclusive North American licensing agreement for opicapone . Neurocrine will be responsible for development and commercialization of opicapone in united states and canada . Will make upfront payment of $30 million and will fund all development activities necessary for U.S. FDA approval . Will pay Bial a percentage of net sales in exchange for manufacture and supply of opicapone drug product . Neurocrine Biosciences - upon completion of technology transfer from Bial, neurocrine intends to meet with fda to discuss potential NDA submission .Neurocrine Biosciences - Bial eligible to receive additional milestone payments of about $115 million from neurocrine for achievement of certain milestones.  Full Article

Neurocrine says INGREZZA NDA for treatment of tardive dyskinesia has been accepted for priority review by U.S. FDA
Tuesday, 11 Oct 2016 

Neurocrine Biosciences Inc : Neurocrine announces INGREZZA™ (valbenazine) new drug application for the treatment of tardive dyskinesia has been accepted for priority review by U.S. FDA .Neurocrine Biosciences Inc- INGREZZA application has been given a prescription drug user fee act (PDUFA) target action date of April 11, 2017.  Full Article

Neurocrine announces FDA conditional acceptance of Ingrezza
Thursday, 1 Sep 2016 

Neurocrine Biosciences Inc : Neurocrine announces FDA conditional acceptance of proprietary name Ingrezza™ for VMAT2 inhibitor valbenazine .Expects to receive notification of acceptance of NDA filing, as well as timeframe for NDA review from FDA in October 2016.  Full Article

BRIEF-Neurocrine Biosciences Presents Long-Term Data Analyses From Open-Label Kinect 4 Phase III Study

* NEUROCRINE BIOSCIENCES PRESENTS LONG-TERM DATA ANALYSES FROM OPEN-LABEL KINECT 4 PHASE III STUDY DEMONSTRATING INGREZZA® IMPROVES TARDIVE DYSKINESIA SYMPTOMS Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)